text_1: B3-Galectin decreases cell resistance to tyrosine kinase inhibitors (TKIs) by engaging the alternate KRAS-RalB signaling complex downstream of EGFR.
text_2: Pharmacological targeting of this pathway with bortezomib reversed both tumour stemness and erlotinib resistance.